BAFFR (B- cell-activating factor receptor), also known as CD268 and BR3 (BLyS receptor 3), is a single-pass type III transmembrane glycoprotein in the tumor necrosis factor receptor superfamily (TNFRSF13C).  BAFFR contains only one partial TNFR cysteine-rich repeat with 4 cysteine residues in the extracellular region but lacks a cytoplasmic death domain (DD). BAFFR is highly expressed in spleen and lymph node, and in resting B-cells. BAFFR is detected at lower levels in activated B-cells, resting T-cells, in thymus and peripheral blood leukocytes. BAFFR is a B-cell receptor specific for the TNF superfamily ligand, BAFF /TNFSF13B. BAFF promotes the survival of B cells and is essential for B cell maturation.  BAFF binds to3 TNFRSF members: BCMA (B­cell maturation antigen - TNFRSF17), TACI (transmembrane activator and calcium­modulator and cyclophilin ligand interactor -TNFRSF13B) and BAFFR. TACI and BCMA bind BAFF and another TNFSF ligand, APRIL (a proliferation­inducing ligand). In contrast, BAFFR selectively binds BAFF. BAFF knockout mice lack mature B cells while BCMA­ or TACI­deficient mice have no major defect in B­cell development. Mutations in the BAFFR gene are associated with immunodeficiency common variable type 4 (CVID4), which is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. CVID4 results from a failure of B-cell differentiation and impaired secretion of immunoglobulins.

BAFFR (B- cell-activating factor receptor), also known as CD268 and BR3 (BLyS receptor 3), is a single-pass type III transmembrane glycoprotein in the tumor necrosis factor receptor superfamily (TNFRSF13C).  BAFFR contains only one partial TNFR cysteine-rich repeat with 4 cysteine residues in the extracellular region but lacks a cytoplasmic death domain (DD). BAFFR is highly expressed in spleen and lymph node, and in resting B-cells. BAFFR is detected at lower levels in activated B-cells, resting T-cells, in thymus and peripheral blood leukocytes. BAFFR is a B-cell receptor specific for the TNF superfamily ligand, BAFF /TNFSF13B. BAFF promotes the survival of B cells and is essential for B cell maturation.  BAFF binds to3 TNFRSF members: BCMA (B­cell maturation antigen - TNFRSF17), TACI (transmembrane activator and calcium­modulator and cyclophilin ligand interactor -TNFRSF13B) and BAFFR. TACI and BCMA bind BAFF and another TNFSF ligand, APRIL (a proliferation­inducing ligand). In contrast, BAFFR selectively binds BAFF. BAFF knockout mice lack mature B cells while BCMA­ or TACI­deficient mice have no major defect in B­cell development. Mutations in the BAFFR gene are associated with immunodeficiency common variable type 4 (CVID4), which is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. CVID4 results from a failure of B-cell differentiation and impaired secretion of immunoglobulins.

  

Product Details

 

Gene Symbol: TNFRSF13C; CD268; BR3; CVID4; BAFF-R; BROMIX; prolixin

 

NCBI Gene ID: 115650

 

Uniprot Entry: Q96RJ3

 

Construct Details: The recombinant human BAFFR-Fc fusion is expressed as a 300 amino acid protein consisting of Arg2 - Gly76 region of BAFFR (UniProt accession #Q96RJ3) and a C-terminal Fc from human IgG1, which exists as a dimer/tetramer/oligomer under non-reducing conditions (see the gel image inserted above).  

   

Source: Human cells stably expressing human BAFFR-Fc and growing in chemical-defined media with no animal components or antibiotics

 

Deduced Amino Acid Sequence: 

        10         20         30         40         50         60 

RRGPRSLRGR DAPAPTPCVP AECFDLLVRH CVACGLLRTP RPKPAGASSP APRTALQPQE 

        70         80         90        100        110        120 

SVGAGAGEAA LPLPGTHTCP PCPAPELLGG PSVFLFPPKP KDTLMISRTP EVTCVVVDVS 

       130        140        150        160        170        180 

HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK EYKCKVSNKA 

       190        200        210        220        230        240 

LPAPIEKTIS KAKGQPREPQ VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP 

       250        260        270        280        290        300 

ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK

 

M.W.: Calculated molecular mass (kDa): 33; Estimated by SDS-PAGE under reducing condition (kDa): 40-45

 

Calculated PI: 8.62

 

Calculated extinction coefficients (M-1 cm-1, at 280nm): 36035

 

Purity: >95% judged by SDS-PAGE under reducing condition (see the gel image above, labeled as "DTT: +")

 

Formulation: Supplied at 0.5 mg/ml in sterile PBSpH7.4 (carrier & preservative free). The purified recombinant protein was labeled with Biotin (3-5 Biotin per molecule) using the standard procedure.

 

Endotoxin Level: <0.1 EU per 1 μg of purified recombinant protein determined by the LAL method

 

Biological Activity: Binds to its ligand BAFF.  Inhibits  BAFF-mediated signaling activities including NF-κB activation and proliferation of anti­-IgM co-stimulated B cells.

 

 

  

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.

 

Storage

 

The product is shipped at 4°C. Upon receipt, centrifuge the product briefly before opening the vial. It is recommended to store small aliquots at the temperature below –20°C for long-term storage and the product is stable for 3 months. The undiluted protein can be stored at 4°C for no more than 2 weeks.

 

 

 

 

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

 

References

 

1. Science 14:2108 (2001).

2. Current Biol. 11:R1013 (2001).

3. Nat. Rev. Immunol. 2:464 (2002).

4. Curr. Opin. Immunol. 14:266 (2002).

5. Adv. Cancer Res.86: 195 (2003). 

 

 

 

Documentation

 

Product datasheet (pdf) can be downloaded here: FCL0108B-PDS.pdf

 

 

 

Additional supporting documents, including COA and MSDS are available upon request.

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.